Orkambi improves lung function and reduces pulmonary exacerbations in people with cystic fibrosis who have two copies of the F508del mutation
The New England Journal of Medicine ( NEJM ) has published data from the two phase 3 studies of Orkambi ( Lumacaftor / Ivacaftor ), an investigational medicine designed to treat the underlying cause o ...
read article